Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Immunology

• Publication date

  2014-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/eji.201344433PMID 25042008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication

  2013cited by this paper
• Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

  2012cited by this paper
• mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

  2012cited by this paper
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

  2012cited by this paper
• Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.

  2011cited by this paper
• Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.

  2011cited by this paper
• Interleukin-21-Producing HIV-1-Specific CD8 T Cells Are Preferentially Seen in Elite Controllers

  2010cited by this paper
• Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

  2010cited by this paper
• Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control

  2010cited by this paper
• IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection

  2009cited by this paper
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

  2009cited by this paper
• Preparation for antiretroviral interruption by boosting the immune system

  2008cited by this paper
• Preserved Central Memory and Activated Effector Memory CD4+ T-Cell Subsets in Human Immunodeficiency Virus Controllers: an ANRS EP36 Study

  2007cited by this paper
• HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

  2007cited by this paper
• Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases

  2006cited by this paper
• Regulating the immune response to tumours.

  2006cited by this paper
• Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients

  2005cited by this paper
• CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection

  2004cited by this paper
• Loss of HIV-1–specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1–specific CD4+ T Cells

  2004cited by this paper
• Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

  2004cited by this paper
• Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

  2004cited by this paper
• Combining several ordinal measures in clinical studies

  2004cited by this paper
• Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4+ and CD8+ T Cell Responses1

  2002cited by this paper
• THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY

  2001cited by this paper
• On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics

  2000cited by this paper
• Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine

  2000cited by this paper
• The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses

  1998cited by this paper
• Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

  1997cited by this paper

• A review of vaccinology and ex vivo antigen-loaded dendritic cells: A different approach to infectious disease vaccines

  2025cites this paper
• Neutrophils induce effective antibody responses to the pneumococcal conjugate vaccine by inhibiting regulatory T cells

  2025cites this paper
• Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1

  2025cites this paper
• Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist.

  2025cites this paper
• Immunostimulatory effects of Hsp70 fragments-modified DCs: A computational and experimental study in HIV vaccine design.

  2025cites this paper
• Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile

  2025cites this paper
• Navigating the Roadblocks: Progress and Challenges in Cell‐Based Therapies for Human Immunodeficiency Virus

  2024cites this paper
• Definition of Virological Endpoints Improving the Design of Human Immunodeficiency Virus (HIV) Cure Strategies Using Analytical Antiretroviral Treatment Interruption.

  2024cites this paper
• A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease

  2024cites this paper
• Viral T-cell epitopes - Identification, characterization and clinical application.

  2023cites this paper
• Between group comparison of AUC in clinical trials with censored follow-up: Application to HIV therapeutic vaccines

  2023cites this paper
• Dendritic Cells - Win the Fight Against HIV.

  2022cites this paper
• The Rational Combination Strategy of Immunomodulatory Latency Reversing Agents and Novel Immunotherapy to Achieve HIV-1 Cure

  2022cites this paper
• Different dendritic cells-based vaccine constructs influence HIV-1 antigen-specific immunological responses and cytokine generation in virion-exposed splenocytes.

  2022cites this paper
• Refining the DC-targeting vaccination for preventing emerging infectious diseases

  2022cites this paper
• T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial

  2022cites this paper
• Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX—a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine

  2022cites this paper
• Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes.

  2021cites this paper
• Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

  2021cites this paper
• Poly I:C and STING agonist‐primed DC increase lymphoid tissue polyfunctional HIV‐1‐specific CD8+ T cells and limit CD4+ T‐cell loss in BLT mice

  2021cites this paper
• Contributions to Random Forests Methods for several Data Analysis Problems

  2021cites this paper
• Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines

  2021cites this paper
• Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells

  2021cites this paper
• Co‐immunization with L‐Myc enhances CD8+ or CD103+ DCs mediated tumor‐specific multi‐functional CD8+ T cell responses

  2021cites this paper
• A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial

  2021cites this paper
• Honing the T cell response to HIV: Turning off the noise

  2021cites this paper
• Advances toward a cure for HIV: getting beyond n=2.

  2020cites this paper
• Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV.

  2020cites this paper
• Bayesian mixture models for cytometry data analysis

  2020cites this paper
• Immunological approaches to HIV cure.

  2020cites this paper
• Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response

  2020cites this paper
• The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination

  2020cites this paper
• Dendritic cells focus CTL responses toward highly conserved and topologically important HIV epitopes

  2020cites this paper
• CD8+ T cells in HIV control, cure and prevention

  2020cites this paper
• Monocytes complexed to platelets differentiate into functionally deficient dendritic cells

  2020cites this paper
• The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook

  2020cites this paper
• Plasmacytoid Dendritic Cells as Cell-Based Therapeutics: A Novel Immunotherapy to Treat Human Immunodeficiency Virus Infection?

  2020cites this paper
• Therapeutic Vaccines for the Treatment of HIV.

  2020cites this paper
• The quest for faithful in vitro models of human dendritic cells types.

  2020cites this paper
• Therapeutic HIV vaccines and broadly neutralizing antibodies.

  2020cites this paper
• Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

  2020cites this paper
• Novel prime-boost vaccine strategies against HIV-1

  2019cites this paper
• Comparative analysis and generation of a robust HIV-1 DNA quantification assay.

  2019cites this paper
• Phenotypic and functional profile of IFN-α-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals

  2019cites this paper
• Clinical trials of antiretroviral treatment interruption in HIV-infected individuals

  2019cites this paper
• Random forests for high-dimensional longitudinal data

  2019cites this paper
• Benefits of dimension reduction in penalized regression methods for high-dimensional grouped data: a case study in low sample size

  2019cites this paper
• Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1

  2019cites this paper
• Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals

  2019influential citation
• Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology

  2019cites this paper
• Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination

  2019cites this paper
• Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses

  2019cites this paper
• Genetic regulation of gene expression and splicing during a 10-year period of human aging

  2019cites this paper
• Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect.

  2019cites this paper
• Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill

  2019cites this paper
• Statistical approaches and methodological developments to optimize clinical vaccine research

  2019cites this paper
• TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs

  2018cites this paper
• HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates

  2018cites this paper
• Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.

  2018cites this paper
• Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment

  2018cites this paper
• Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses

  2018cites this paper
• Therapeutic vaccination for HIV: hopes and challenges

  2018cites this paper
• Sparse partial least squares with group and subgroup structure

  2018cites this paper
• Lessons learned from HIV antiretroviral treatment interruption trials

  2018cites this paper
• Immune Interventions to Eliminate the HIV Reservoir.

  2018cites this paper
• Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity

  2018cites this paper
• HIV-1 Latency

  2018cites this paper
• Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies

  2018influential citation
• Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?

  2018cites this paper
• Generalized estimating equations by considering additive terms for analyzing time-course gene sets data

  2018cites this paper
• Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy.

  2018cites this paper
• Visualizing omics and clinical data: Which challenges for dealing with their variety?

  2018cites this paper
• Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients

  2017cites this paper
• Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine

  2017cites this paper
• New challenges in therapeutic vaccines against HIV infection

  2017influential citation
• Systems immunology: just getting started

  2017cites this paper
• Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice

  2017cites this paper
• An immunoregulatory role of dendritic cell-derived exosomes versus HIV-1 infection: take it easy but be warned.

  2017influential citation
• Combined Single-Cell Measurement of Cytokine mRNA and Protein Identifies T Cells with Persistent Effector Function

  2017cites this paper
• A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

  2017cites this paper
• Sequential Dirichlet process mixtures of multivariate skew $t$-distributions for model-based clustering of flow cytometry data

  2017cites this paper
• Targeted Immune Interventions for an HIV-1 Cure.

  2017cites this paper
• Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines

  2017cites this paper
• Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

  2017cites this paper
• Distance-correlation based gene set analysis in longitudinal studies

  2016cites this paper
• Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection

  2016cites this paper
• Immunological strategies to target HIV persistence

  2016cites this paper
• Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change

  2016cites this paper
• Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy

  2016cites this paper
• This information is current as Cells with Persistent Effector Function Cytokine mRNA and Protein Identifies T Combined Single-Cell Measurement of

  2016cites this paper
• Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection

  2016cites this paper
• Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

  2016influential citation
• HIV-1 prophylactic vaccines: state of the art

  2016cites this paper
• Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis

  2016influential citation
• Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy

  2016cites this paper
• T lymphocyte inhibitory/exhaustion marker expression in chronic HIV-1 infection and the impact of TB co-infection

  2016cites this paper
• T-Regulatory Cells and Vaccination “Pay Attention and Do Not Neglect Them”: Lessons from HIV and Cancer Vaccine Trials

  2016cites this paper
• Dendritic Cells in Viral Infection

  2016cites this paper
• Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.

  2016cites this paper
• Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.

  2015cites this paper